ERBB2 and breast carcinoma: It is well established that HER2 status is associated with improved outcomes in patients treated with cytotoxic chemotherapy in breast cancer and hypothesized that this may reflect these patients having a better baseline functional status, since that is required to receive platinum-based therapy, given the high side-effect profile [9].